DEA schedule
Is Dayvigo a controlled substance?
Dayvigo contains lemborexant. Federal schedule from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
Yes. Dayvigo (lemborexant) is a Schedule IV controlled substance under the federal Controlled Substances Act. Matching DEA list entry: Lemborexant (Schedule IV).
Run it in Rivvi
Which 2027 plans near you dropped or restricted Dayvigo?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 2 prescription listings from 1 labelers, all Schedule IV |
| DEA controlled substances list | Lemborexant: Schedule IV |
DEA list entry
| Substance | DEA code | Schedule | Narcotic | Other names | Match |
|---|---|---|---|---|---|
| Lemborexant | 2245 | IV | No | (1R,2S)-2-[(2,4-Dimethylpyrimidin-5-yl)oxymethyl]-2- | Listed by name |
Dayvigo NDC listings
Questions
Is Dayvigo a controlled substance?
Yes. Dayvigo (lemborexant) is a Schedule IV controlled substance under the federal Controlled Substances Act. Matching DEA list entry: Lemborexant (Schedule IV).
Is Dayvigo a narcotic?
No. The DEA list does not mark lemborexant as a narcotic (NARC = N) and places it in Schedule IV. Its FDA established pharmacologic class is Orexin Receptor Antagonist.
What schedule is Dayvigo?
Dayvigo is Schedule IV in the FDA NDC directory, which matches the DEA controlled substances list.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.